 Aduro Biotech, Inc. ADRO, a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes STING and A Proliferation Inducing Ligand APRIL pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the company will host a live conference call and webcast on Monday, June 8, 2020 at 1:00 pm PDT to report data in healthy volunteers from the ongoing Phase 1 study of BION-1301 for the treatment of IgA nephropathy IgAN as well as data from long-term nonclinical studies. Members of the Aduro executive team will be joined by Dr. Jonathan Barratt, the Mayer Professor of Renal Medicine at University of Leicester. 